Gemcitabine

證據等級: L5

預測適應症: 10 個

Gemcitabine: From Pancreatic Cancer to Female Breast Carcinoma

One-Sentence Summary

Gemcitabine is a conventional cytotoxic nucleoside analog with established global approvals for pancreatic cancer, non-small cell lung cancer, and bladder cancer, though it currently holds no registration in Singapore. The TxGNN model predicts it may be effective for Female Breast Carcinoma, a prediction strongly grounded in biology — the FDA has already approved Gemcitabine (in combination with paclitaxel) for metastatic breast cancer following anthracycline failure. This direction is supported by over 50 clinical trials and 20 publications identified in the evidence review, with multiple completed Phase 3 RCTs underpinning an L1 evidence level.

Quick Overview

Item	Content
Original Indication	Pancreatic cancer (primary global approval; no Singapore registration on record)
Predicted New Indication	Female Breast Carcinoma
TxGNN Prediction Score	99.98%
Evidence Level	L1
Singapore Market Status	✗ Not marketed (0 HSA registrations)
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Gemcitabine is a pyrimidine nucleoside antimetabolite. After intracellular phosphorylation, it competitively inhibits DNA polymerase (causing chain termination) and irreversibly inhibits ribonucleotide reductase (RRM1), depleting the deoxynucleotide pools needed for DNA synthesis. This leads to S-phase arrest and apoptosis. Critically, Gemcitabine exhibits self-potentiation: by depleting dCTP pools, it increases its own incorporation into DNA, amplifying cytotoxicity — a property that makes it particularly effective in rapidly dividing epithelial tumours.

Breast cancer cells are known to overexpress RRM1, making them mechanistically susceptible to Gemcitabine. More importantly, Gemcitabine and taxanes (paclitaxel, docetaxel) display complementary and synergistic mechanisms: taxanes stabilise microtubules and arrest cells in G2/M, while Gemcitabine drives S-phase arrest and sensitises tumour cells to subsequent DNA damage. This synergy is not merely theoretical — the FDA has formally approved Gemcitabine + Paclitaxel for metastatic breast cancer that has progressed after anthracycline-containing chemotherapy, making this one of the most scientifically validated repurposing examples in oncology.

The TxGNN score of 99.98% is therefore not surprising: the knowledge graph correctly identifies the mechanistic and clinical overlap between Gemcitabine's established oncology profile and breast cancer biology. The absence of Singapore registration reflects a regulatory filing gap rather than a clinical evidence gap. A robust body of Phase 2 and Phase 3 trial data — spanning adjuvant, neoadjuvant, and metastatic settings — across multiple breast cancer subtypes (TNBC, HER2+, HR+) exists globally, providing a strong foundation for regulatory consideration.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00039546	Phase 3	Unknown	~800	tAnGo Trial: Randomised comparison of Paclitaxel–Epirubicin–Cyclophosphamide ± Gemcitabine as adjuvant chemotherapy for ER/PgR-poor early breast cancer — the core Phase 3 RCT directly evaluating Gemcitabine addition in breast cancer adjuvant setting
NCT00006459	Phase 3	Completed	N/A	Gemcitabine + Paclitaxel vs Paclitaxel alone for unresectable/locally recurrent or metastatic breast cancer — landmark Phase 3 study that formed the basis for FDA approval of this combination
NCT00561119	Phase 3	Completed	326	Maintenance vs observation after achieving clinical response with Gemcitabine + Paclitaxel (GP) first-line chemotherapy in metastatic breast cancer; evaluates durability of GP regimen
NCT00408408	Phase 3	Unknown	1,206	Neoadjuvant: Adding Capecitabine or Gemcitabine to Docetaxel before AC ± Bevacizumab in palpable, operable breast cancer; primary endpoint is pathological complete response (pCR)
NCT00110084	Phase 2	Completed	50	Weekly nab-Paclitaxel + Gemcitabine for metastatic breast cancer; demonstrates efficacy and safety of this albumin-bound taxane combination
NCT02252887	Phase 2	Completed	45	Gemcitabine + Trastuzumab + Pertuzumab for HER2-positive metastatic breast cancer after prior anti-HER2–based therapy; evaluates dual HER2 blockade with chemotherapy backbone
NCT06027268	Phase 2	Active, not recruiting	36	ToPCourT: Trilaciclib + Pembrolizumab + Gemcitabine + Carboplatin for locally advanced or metastatic triple-negative breast cancer (TNBC); assesses myeloprotection combined with immunotherapy–chemotherapy
NCT00027989	Phase 2	Unknown	N/A	Liposomal Doxorubicin (Doxil) + Gemcitabine for metastatic breast cancer; evaluates an anthracycline-avoiding combination in pretreated patients
NCT00003540	Phase 2	Completed	30	Gemcitabine monotherapy for metastatic breast cancer previously treated with doxorubicin and paclitaxel; establishes single-agent activity in heavily pretreated disease
NCT00014456	Phase 1	Completed	35	Docetaxel + Gemcitabine + Filgrastim (G-CSF) dose escalation for advanced solid tumours including breast cancer; provides safety profile and recommended doses for combination use

Literature Evidence

PMID	Year	Type	Journal	Key Findings
14719116	2004	Review (Mechanism)	Int J Oncol	Comprehensive rationale for Gemcitabine in breast cancer: reviews pyrimidine antimetabolite mechanism (self-potentiation, RRM1 inhibition), single-agent and combination activity data
12138397	2002	Review	Semin Oncol	~20 Phase 2 trials confirm Gemcitabine single-agent response rates of 16–37% in metastatic breast cancer (first-line and refractory); reviews combinations with taxanes, platinum, and targeted agents
15685819	2004	Review	Oncology	Gemcitabine + Paclitaxel in metastatic breast cancer: 52% response rate across Phase 2 trials; reviews scheduling (day 1/8 every 3 weeks vs day 1/14 every 4 weeks) and toxicity management
14768404	2003	Review/Meta-analysis	Oncology	Gemcitabine combined with anthracyclines and taxanes for advanced breast cancer; summarises impressive response rates and survival data from prospective studies
15685821	2004	Cohort	Oncology	Gemcitabine + platinum compounds in metastatic breast cancer: significant clinical benefit and response rates documented; positions this combination for anthracycline/taxane-refractory patients
14754468	2004	Retrospective Cohort	Clin Breast Cancer	Gemcitabine + platinum in anthracycline- and taxane-pretreated breast cancer; non–cross-resistant profile and favourable tolerability supports use in sequential therapy
12057038	2002	Review	Clin Breast Cancer	Overview of Gemcitabine as single-agent in advanced breast cancer; describes unique self-potentiation mechanism and role in an era of increasingly complex treatment sequencing
40779028	2025	Phase 1/2	Breast Cancer Res Treat	Carboplatin + Gemcitabine + Mifepristone (GR antagonist) for advanced breast and ovarian cancer; demonstrates that GR antagonism with mifepristone enhances Gemcitabine cytotoxicity in GR-positive tumours
38262235	2024	Phase 1	Gynecol Oncol	Mirvetuximab soravtansine + Gemcitabine for FRα-positive TNBC (and ovarian/endometrial cancer); establishes MTD and recommended Phase 2 dose for the TNBC cohort
25398698	2015	Cohort	Cancer Chemother Pharmacol	Docetaxel + Gemcitabine + Bevacizumab biweekly for HER2-negative metastatic breast cancer; evaluates activity and safety as salvage chemotherapy in pretreated patients

Singapore Market Information

Gemcitabine is currently not registered with the Health Sciences Authority (HSA) of Singapore. No product authorisations are on record.

Registration	Status
HSA (Singapore)	No registrations found

Context for Decision-Making: Gemcitabine is widely approved and commercially available in major reference markets. Key approvals include:

FDA (USA): Pancreatic cancer, NSCLC, bladder cancer, and metastatic breast cancer (in combination with paclitaxel after anthracycline failure)

EMA (Europe): Pancreatic cancer, NSCLC, bladder cancer, breast cancer, and ovarian cancer

Multiple Asian markets (Japan, Korea, Taiwan, etc.)

For Singapore clinical use, Gemcitabine may be accessed through the HSA's Special Access Route (SAR) while a formal registration application is pursued.

Cytotoxicity

Gemcitabine is a conventional cytotoxic antineoplastic agent classified as a nucleoside analog/antimetabolite. This section applies.

Item	Content
Cytotoxicity Classification	Conventional cytotoxic — Nucleoside Analog / Antimetabolite (Fluoropyrimidine-related class)
Myelosuppression Risk	High — Neutropenia is the primary dose-limiting toxicity; thrombocytopenia and anemia are also common. G-CSF support (e.g., filgrastim) is frequently used in combination regimens. Nadir typically at day 8–14
Emetogenicity Classification	Low to Moderate — Gemcitabine monotherapy is low emetogenic risk; moderate risk when combined with carboplatin or cisplatin (per MASCC/ESMO classification)
Monitoring Items	CBC with differential and platelet count (before each cycle and on day 8); liver function tests (ALT, AST, bilirubin, alkaline phosphatase); renal function (serum creatinine, eGFR); pulmonary function assessment if new respiratory symptoms emerge (risk of gemcitabine-induced pneumonitis)
Handling Protection	Cytotoxic handling regulations apply — closed-system drug transfer devices (CSTDs) required for preparation; full PPE (gloves, gown, eye protection) for pharmacists and nurses; dedicated preparation in a biological safety cabinet

Safety Considerations

Detailed safety data (key warnings, contraindications, drug interactions) were not available in this Evidence Pack.

Please refer to the current package insert (US Prescribing Information or EU Summary of Product Characteristics) for complete safety information. Known areas of clinical importance include: pulmonary toxicity (interstitial pneumonitis, pulmonary oedema), haemolytic uraemic syndrome (HUS), hepatotoxicity, capillary leak syndrome, and radiation sensitisation effects. Formal TFDA/HSA package insert review is required before any clinical application in Singapore (see Data Gap DG001).

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The TxGNN prediction of 99.98% is mechanistically justified and clinically validated — Gemcitabine already holds FDA and EMA approval for breast cancer in combination with paclitaxel, underpinned by completed Phase 3 RCTs (tAnGo, NCT00006459) and a large body of Phase 2 evidence across all major breast cancer subtypes. The L1 evidence level represents one of the strongest drug repurposing cases in this dataset. The primary barrier to use in Singapore is the absence of an HSA registration, not a lack of clinical evidence.

To proceed, the following is needed:

Regulatory pathway: Initiate HSA product registration application for the breast cancer indication, using FDA/EMA approvals as reference; in the interim, apply for Special Access Route (SAR) authorisation for individual patients
Safety data completion (DG001 — Blocking): Obtain and review the full package insert (USPI or SmPC), specifically extracting key warnings (pulmonary toxicity, HUS, hepatotoxicity), contraindications, and dose-modification guidelines
MOA documentation (DG002 — High): Retrieve structured mechanism-of-action data from DrugBank API to support clinical decision support integration
Subtype targeting strategy: Define the intended breast cancer subtype(s) — TNBC (Gemcitabine + Carboplatin or + Pembrolizumab), HER2+ (Gemcitabine + Trastuzumab ± Pertuzumab), or HR+ (salvage setting) — and align with current NCCN/ESMO guidelines
Drug interaction assessment: Conduct formal DDI review, particularly for combinations with anti-HER2 agents, immune checkpoint inhibitors, and CDK4/6 inhibitors
Local safety monitoring plan: Develop a site-specific monitoring protocol covering CBC nadir management, pulmonary surveillance, and renal function monitoring appropriate for the Singapore oncology setting
Supply chain confirmation: Verify availability of Gemcitabine (as Gemzar® or approved generic) through licensed Singapore importers or regional distributors
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.